SCHEDULE: Lytton Discloses 7.2% Stake in TELA Bio

Laurence W. Lytton has reported a 7.2% beneficial ownership stake in TELA Bio, Inc., holding 2,865,305 shares of common stock as of September 30, 2025.

Summary

• Laurence W. Lytton beneficially owns 2,865,305 shares of TELA Bio, Inc. common stock.
• This ownership represents 7.2% of the company's outstanding common stock.
• The percentage is calculated based on 39,616,440 shares of Common Stock outstanding as of August 4, 2025, as reported in TELA Bio, Inc.'s Form 10-Q for the quarter ended June 30, 2025.
• Lytton holds sole voting power and sole dispositive power over all 2,865,305 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of TELA Bio, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a 7.2% beneficial ownership by Laurence W. Lytton indicates a substantial investment in TELA Bio, Inc. This can be interpreted as a positive signal of investor confidence in the company's long-term value, particularly given the certification of a passive investment intent.

Positives

• A significant beneficial ownership stake of 7.2% by an individual investor, Laurence W. Lytton, may signal confidence in TELA Bio, Inc.'s future prospects.
• The investor's certification of a passive investment intent, not seeking to influence control (except for potential nominations), suggests a long-term, supportive stance.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding TELA Bio, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of beneficial ownership by an individual investor and does not provide specific insights into broader industry trends or the competitive landscape for TELA Bio, Inc. However, significant individual stakes can sometimes precede increased shareholder activism or engagement, which is a common dynamic across various industries.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an individual investor may instill confidence and potentially influence market perception of the stock.
• Management: Awareness of a large, passive shareholder may influence management's strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant, passive stake by an individual investor, which is generally a positive signal of confidence. However, a Schedule 13G filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial existing position. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while awaiting further operational updates from TELA Bio, Inc.

Keywords

TELA Bio, TLAB, Laurence W. Lytton, beneficial ownership, Schedule 13G, common stock, equity stake, investor disclosure